Based on a complaint concerning the biologically active supplement (BAS) “Triortasol Orosol+Zinc” produced by “ORIENT BIOPHARM” LLC, the Competition Promotion and Consumer Protection Committee of the Republic of Uzbekistan, in cooperation with the Sanitary-Epidemiological Safety and Public Health Committee, conducted a review.
The review revealed that changes had been made to the packaging design and usage instructions of this product without proper authorization and without coordination with the Sanitary-Epidemiological Committee, thereby violating established procedures.
It was also noted that the composition and packaging information of “Triortasol Orosol+Zinc” was similar to the previously manufactured drug “ORSA.”
As a result of the identified violations, “ORIENT BIOPHARM” LLC was issued the following requirements:
-
to re-develop the “Orosol” BAS in accordance with the documents submitted with the license and to temporarily suspend its production,
-
to withdraw from retail networks the “Triortasol Orosol+Zinc” product manufactured without a license, based on a sanitary order.
The collected documents were forwarded to the “Uzbekistan Accreditation Center” for review in accordance with the established procedure.
The Competition Promotion and Consumer Protection Committee of the Republic of Uzbekistan officially warns all producers and importers of biologically active supplements that they must provide consumers only with information that complies with legislation and is duly approved.
